Search Results 2131-2140 of 21327 for anti-TNF drugs

1. Glycopyrrolate (Oral Route) Before Using - Mayo Clinic

   Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

2. Bexarotene (Topical Route) Description and Brand Names - Mayo Clinic

   Bexarotene belongs to the group of medicines known as retinoids (RET-i-noyds). When applied to the skin, it is used to treat a form a cancer called cutaneous T- ...

3. Publications - Anastasia Zekeridou, M.D., Ph.D. - Mayo Clinic

   Drugs & Supplements · Healthy Lifestyle · Books ... Drugs & Supplements ... High-resolution epitope mapping of anti-Hu and anti-Yo autoimmunity by programmable ...

4. A Study to Assess the Effectiveness of Osimertinib Plus Savolitinib in Patients with Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Osimertinib Treatment (SAVANNAH Study) Following Prior Osimertinib - Mayo Clinic

   By condition, treatment or drug ... anti-coagulation which affects these parameters. ... Any cytotoxic chemotherapy, investigational agents or other anticancer ...

5. Scopolamine (Transdermal Route) Before Using - Mayo Clinic

   Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

6. Tiotropium (Inhalation Route) Proper Use - Mayo Clinic

   Proper Use. Drug information provided by: Merative, Micromedex®. Use this medicine only as directed by your doctor. Do not use more of it, do not use it ...

7. Poor antibody response for COVID vaccine in patients with cancer - Mayo Clinic

   The other 36 were patients with cancer who were not on an immunosuppressive therapy. Of the 140 immunocompromised patients, 91 had hematologic malignancies and ...

8. A Study to Evaluate Pembrolizumab, Ixazomib Citrate, and Dexamethasone to Treat Participants with Relapsed Multiple Myeloma - Mayo Clinic

   Must have relapsed or refractory disease after treatments including three therapies: proteasome inhibitors, immunomodulatory imide drugs (IMiDs), and anti-CD38 ...

9. A Study of SC‑004 in Subjects With Advanced Solid Tumors - Mayo Clinic

   Prior therapy with any agents targeting immune co-inhibitory receptors (eg, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-cytotoxic T lymphocyte-associated ...

10. Mayo Clinic Supplier Information - About Us

    Mayo Clinic Supply Chain Management supports this mission through the provision of products and information that directly support patient care. Each year, Mayo ...